Pfizer's mature products business, to be merged with Mylan, took a tumble in China in Q2. Is that an ill omen for the rest of Big Pharma?

Pfizer knew things would take a turn after generics for its blockbuster Lyrica launched stateside in July. But did it know it would be this bad?

The second of AbbVie’s highly anticipated 2019 blockbuster candidates is here: Its crucial Humira follow-up, Rinvoq.

And the winner is Publicis Groupe. Novartis has selected the agency to handle its global media account under a newly created group, NovartisONE2.

Amarin may still be waiting for the FDA to include new risk-reduction info to Vascepa's label, but in the meantime, it's getting prepared.

Bristol-Myers Squibb’s takeover of Celgene hasn’t always gone smoothly, but now a once-left-for-dead centerpiece of that deal is ready to launch.

Two of Roche’s oncology blockbusters are facing dire straits with biosims on the march. Now, a major insurer and PBM is betting on the new guys.

Valeant changed its name to Bausch Healthcare to distance itself from scandal, but one of its old strategies hasn't gone anywhere, an analyst says.

Investors sued Novo Nordisk in Denmark, claiming it misled the public about trouble plaguing its insulin franchise—and demanding $1.75B in damages.